Investor Presentaiton

ORION Oncology and Pain focus areas of R&D Proven track record in oncology 2 approved innovative medicines Proven track record in CNS FARESTON A NUBEQA™ (darolutamide) 4 Comtess approved 300 mg tablets innovative Stalevo medicines Precedex® (dexmedetomidine HCI Injection) dexdor dalsmedetomidin 9 2 world-class partnerships with big pharma 6 phase III trials in prostate cancer BAYER BAYER MERCK CNS focus 2 finalised and 2 ongoing with Bayer on darolutamide • 2 ongoing with Merck on ODM-208 (MK- 5684) on pain in 2022 Acquisition of ODM-111 Research emphasis in pain Investor Presentation Orion Corporation

View entire presentation